c-Met is a transmembrane receptor tyrosine kinase that is encoded by the MET proto-oncogene and activated upon binding to the hepatocyte growth factor. Dysregulation of c-Met is observed in several types of cancer, including overexpression in approximately 50% of NSCLC. Telisotuzumab vedotin (ABBV-399; Teliso-V) is a first-in-class antibody-drug conjugate (ADC) that uses a cleavable linker to combine a recombinant c-Met–targeting humanized monoclonal antibody (ABT-700) and monomethyl auristatin E (MMAE), a potent inhibitor of microtubule polymerization.
